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Background. We aimed to evaluate treatment responses to atazanavir plus ritonavir (ATV/r) or efavirenz (EFV)
in initial antiretroviral regimens among women and men, and determine if treatment outcomes differ by sex.
Methods. We performed a randomized trial of open-label ATV/r or EFV combined with abacavir/lamivudine
(ABC/3TC) or tenofovir/emtricitabine (TDF/FTC) in 1857 human immunodeficiency virus type 1–infected, treatment-
naive persons enrolled between September 2005 and November 2007 at 59 sites in the United States and Puerto
Rico. Associations of sex with 3 primary study endpoints of time to virologic failure, safety, and tolerability events
were analyzed using Cox proportional hazards models. Model-based population pharmacokinetic analysis was per-
formed using nonlinear mixed effects modeling (NONMEM version VII).
Results. Of 1857 participants, 322 were women. Women assigned to ATV/r had a higher risk of virologic failure
with either nucleoside reverse transcriptase inhibitor backbone than women assigned to EFV, or men assigned to
ATV/r. The effects of ATV/r and EFV upon safety and tolerability risk did not differ significantly by sex. With
ABC/3TC, women had a significantly higher (32%) safety risk compared to men; with TDF/FTC, the safety risk was
20% larger for women compared to men, but not statistically significant. Women had slower ATV clearance and
higher predose levels of ATV compared to men. Self-reported adherence did not differ significantly by sex.
Conclusions. This is the first randomized clinical trial to identify a significantly earlier time to virologic failure
in women randomized to ATV/r compared to women randomized to EFV. This finding has important clinical im-
plications given that boosted protease inhibitors are often favored over EFV in women of childbearing potential.
Clinical Trials Registration. NCT00118898.
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guidelines for human immunodeficiency virus type 1
(HIV-1) indicate that the best choices for first-line
therapy include either efavirenz (EFV), raltegravir, or
the ritonavir-boosted protease inhibitors (PIs) atazana-
vir (ATV/r) or darunavir combined with fixed-dose
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combination tenofovir (TDF) plus emtricitabine (FTC) [1, 2].
Women account for 27% of new HIV-1 infections in the United
States [3]. With the exception of treatment during pregnancy,
there is little in the published literature to suggest that the treat-
ment of choice for treatment-naive patients should be deter-
mined by the patient’s sex [4]. A few adequately powered studies
have examined association of sex with treatment outcome, with
mixed results [5–7].With women comprising a substantial pro-
portion of HIV-1–infected persons in the United States and
globally and given the importance of treatment efficacy for
optimal long-term outcomes, improved understanding of re-
sponses to recommended regimens by sex is needed. This
report summarizes preplanned analyses of AIDS Clinical
Trials Group (ACTG) study A5202 to evaluate treatment
effects on virologic failure, safety, and tolerability by sex.
METHODS
Study Design
A5202 was a phase IIIb, randomized, equivalence study of 4
regimens for initial treatment of HIV-1 conducted at 59 US
and Puerto Rican ACTG sites. Eligible participants were en-
rolled from September 2005 to November 2007, had document-
ed HIV-1, had undergone <8 days of previous antiretroviral
therapy (ART), and were aged 16 years or older. Additional
entry criteria have been published [8, 9]. The human subjects
committees of all sites approved the A5202 protocol, and
written informed consent was obtained from all participants in
compliance with human experimentation guidelines of the US
Department of Health and Human Services.
Participants were randomly assigned to 1 of 4 partially
blinded once-daily regimens: open-label ATV (300 mg, Bristol-
Myers Squibb, Plainsboro, New Jersey) plus ritonavir (100 mg,
Abbott Laboratories, Abbott Park, Illinois) or EFV (600 mg,
Bristol-Myers Squibb) with either placebo-controlled abacavir
(ABC) 600 mg/lamivudine (3TC) 300 mg (GlaxoSmithKline,
Research Triangle Park, North Carolina) or TDF 300 mg/FTC
200 mg (Gilead Sciences, Gilead Sciences, Foster City, Califor-
nia). Randomization was stratified by screening HIV-1 RNA
level (<100 000 or ≥100 000 copies/mL). Further study details
have been published previously [8–10].
Primary efficacy, safety, and tolerability endpoints were time
to (1) virologic failure (VF; confirmed HIV-1 RNA ≥1000
copies/mL at or after 16 weeks and before 24 weeks or ≥200
copies/mL at or after 24 weeks); (2) first grade 3 or 4 sign,
symptom, or laboratory abnormality that was at least
1 grade higher than baseline, excluding unconjugated hy-
perbilirubinemia and creatine kinase; and (3) for the
current analyses, change in assigned antiretroviral third
agent, ignoring changes to nucleoside reverse transcriptase
inhibitors (NRTIs).
ATV Pharmacokinetic Substudy
A sparse sampling strategy approach was designed for measur-
ing steady-state plasma drug levels with an observed dose at 1
or 2 clinic visits during week 4, 8, 16, or 24. Samples were col-
lected before the observed dose and 3–4 hours after the dose. A
third blood sample was collected 5–15 hours after a dose. Ata-
zanavir concentrations were measured using a previously re-
ported and validated reverse-phase high-performance liquid
chromatography method at the University at Buffalo, ACTG
Pharmacology Specialty Laboratory [11].
Statistical Analysis
ACTG A5202 included a preplanned secondary objective to
evaluate VF, safety, and tolerability by sex; however, the study
was not specifically powered for this objective. A detailed de-
scription of the statistical analysis performed to assess the
primary efficacy, safety, and tolerability endpoints has been
published [8–10]. In brief, overall, ATV/r and EFV demonstrat-
ed similar antiviral activity when used with ABC/3TC or with
TDF/FTC [9]. After interim review by an independent data
safety and monitoring board showed a higher VF rate in sub-
jects with screening HIV-1 RNA ≥100 000 copies/mL assigned
to ABC/3TC compared to TDF/FTC (hazard ratio [HR] overall,
2.33 [95% confidence interval {CI}, 1.46–3.72]), these groups
were unblinded to their NRTIs [8]. Secondary analyses found
that this effect differed by sex, and was larger among men (HR,
3.00 [95% CI, 1.74–5.17]) than women (HR, 0.85 [95% CI, .30–
2.39]) with treatment × sex interaction P = .04 [8]. Subjects
with screening HIV-1 RNA <100 000 copies/mL continued to
be followed on blinded treatment through study’s end and had
similar rates of VF in the NRTI groups [10]. Given these
results, current analyses focus on the third drug (non-NRTI)
comparison of ATV/r vs EFV, and these were carried out
within each NRTI arm.
Analyses of VF were intent-to-treat, including all study HIV-1
RNA values starting at randomization; safety data were analyzed
as-treated while on initially assigned third drug. Statistical signif-
icance level for treatment effect modification/interaction test was
a priori set at 0.10. Time-to-event survival distributions were es-
timated by Kaplan-Meier method, and HRs were estimated with
Cox proportional hazards models stratified by screening HIV-1
RNA level. Multivariable analyses were adjusted for baseline age,
race/ethnicity (white, black, Hispanic; other racial groups were
excluded due to small sample sizes), CD4+ lymphocyte count,
plasma HIV-1 RNA, history of AIDS, chronic hepatitis B infec-
tion and hepatitis C, injection drug use history, and whether
screening HIV-1 genotype was performed. Sensitivity analyses
for VF included as-treated analyses. Adherence was categorized
as 100% vs <100% based upon self-report over the preceding 7
days from each visit at weeks 8 and 24 and every 24 weeks there-
after. In post hoc analysis, association between sex and repeated
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measurements of 100% vs <100% adherence at weeks 8, 24, 48,
72, and 96 was evaluated with a generalized estimating equation
model with a logit link and compound symmetry covariance
structure, adjusted for third drug.
Model-based population pharmacokinetic analysis was per-
formed using nonlinear mixed effects modeling (NONMEM
version VII). Individual ATV apparent oral clearance (CL/F)
values were derived using Bayesian estimation from a 1-
compartment population pharmacokinetic structural model. A
separate model-independent analysis included ATV concentra-
tion data from subjects with assay results between 22 and 25
hours postdose (C24h). Each subject’s ATV plasma concentration
vs postdose time profile was reviewed for inconsistencies. Ex-
cluded were those without an ATV concentration between 22
and 25 hours postdose, those with only 1 evaluable ATV concen-
tration, or those with obvious inconsistencies between concen-
tration time points based on the known pharmacokinetic profile
of ATV/r. If a subject had >1 evaluable trough concentration,
results were averaged. The pharmacokinetic concentration data
were natural log-transformed before statistical analysis.
RESULTS
Participant Characteristics
Table 1 compares baseline characteristics of male and female
participants. Women were more likely to have reported black
race, lower creatinine clearance (CrCl), and lower baseline
HIV RNA, and less likely to have undergone genotyping at
screening.
Primary Endpoint Analyses
In Figure 1, time-to-event distributions are illustrated for men
and women for efficacy (Figure 1A), safety (Figure 1B), and tol-
erability (Figure 1C) endpoints. Figure 2 shows the results for
efficacy, safety, and tolerability from Cox proportional hazards
models by assigned treatment arm and sex. As-treated analyses
showed similar results (data not shown).
Efficacy
With ABC/3TC
As shown in Figure 2A, overall ATV/r and EFV had similar vi-
rologic efficacy (HR, 1.13 [95% CI, .82–1.56]), [9] but there was
a significant treatment effect interaction by sex (P = .017). VF
risk was higher among women randomized to ATV/r than to
EFV, with incidence rates (IRs) per 100 person-years of 12.42
vs 4.86, respectively, and an HR of 2.55 (95% CI, 1.20–5.41).
There was no significant difference in VF risk for men assigned
to ATV/r vs EFV, with IRs of 7.41 and 7.77 per 100 person-
years, respectively, and an HR of 0.94 (95% CI, .66–1.34); ad-
justed model showed similar results (interaction P = .006;
Figure 2A).
Comparing women to men, women randomized to ATV/r
had higher VF hazard in multivariable models, with an HR of
1.72 (95% CI, .99–2.99; Figure 2B). Among those randomized
to EFV, there was no significant evidence of increased VF risk
in women vs men (Figure 2B).
Table 1. Baseline Characteristics by Sex
Characteristic Men (n = 1535) Women (n = 322) Total (n = 1857) P Value**
Age, y, mean (SD) 38.1 (10.0) 39.5 (10.2) 38.4 (10.1) .043
>40 y, No. (%) 673 (44) 155 (48) 828 (45) . . .
Race/ethnicity, No. (%) <.001
White, non-Hispanic 689 (45) 57 (18) 746 (40)
Black, non-Hispanic 443 (29) 172 (53) 615 (33)
Hispanica 347 (23) 82 (25) 429 (23)
Otherb 51 (3) 11 (3) 62 (3)
HIV-1 RNA log10 copies/mL, mean (SD) 4.7 (0.7) 4.6 (0.7) 4.7 (0.7) <.001
Screening HIV-1 RNA ≥100 000 copies/mL, No. (%) 676 (44) 121 (38) 797 (43) .033
CD4+ cells/µL, mean (SD) 236 (170) 219 (148) 233 (167) .256
CD4+ <50 cells/µL, No. (%) 278 (18) 61 (19) 339 (18) .104
Genotype results available at entry, No. (%)c 706 (46) 124 (39) 830 (45) .009
History of AIDS, No. (%) 250 (16) 62 (19) 312 (17) .195
Creatinine clearance <90 mL/min, No. (%) 240 (16) 74 (23) 314 (17) .002
Abbreviations: HIV, human immunodeficiency virus; SD, standard deviation.
a Regardless of race.
b Asian, Pacific Islander, Native American, or >1 race; excluded from analysis.
c Genotype was not required at screening, unless recently infected; creatinine clearance calculated based on Crockcoft-Gault equation.
** P value based onWilcoxon and χ2 test for continuous and categorical variables, respectively.
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Figure 1. Time to virologic failure (A), safety (B), and tolerability (C) endpoints by sex. Abbreviations: ABC/3TC, abacabir/lamivudine; ATV/r, atazanavir/
ritonavir; EFV, efavirenz; TDF/FTC, tenofovir/emtricitabine.
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With TDF/FTC
Whereas overall ATV/r and EFV performed similarly (HR, 1.01
[95% CI, .70–1.46]) [9], there was a significant treatment effect
interaction by sex (P = .028). The hazard of VF was higher
among women randomized to ATV/r compared to EFV (IR,
10.90 vs 5.06 per 100 person-years; HR, 2.16 [95% CI, .97–
4.80]). There was no significant difference in VF hazard in men
on ATV/r vs EFV (IR, 4.17 vs 5.23 per 100 person-years; HR,
0.80 [95% CI, .52–1.23]); the adjusted model showed similar
results (Figure 2C).
Comparing women to men, in multivariable models,
women randomized to ATV/r had a higher risk of VF
(HR, 2.36 [95% CI, 1.30–4.26]; Figure 2D). There was no
significant evidence for increased VF in women compared




Overall, subjects treated with ATV/r had a longer time to a
safety endpoint than those treated with EFV (HR, 0.81 [95%
CI, .66–1.00]) [9], and there was no significant evidence that
this effect differed by sex (P = .49); IRs were 31.71 vs 33.96 for
women and 20.81 vs 28.51 for men (Figure 2A).
Overall, compared to men, women had a shorter time to
safety endpoint (HR, 1.32 [95% CI, 1.03–1.70]; Figure 2B).
However, the risk of a safety endpoint for women compared to
men on ATV/r (HR, 1.44 [95% CI, .98–2.10]) or EFV (HR, 1.20
[95% CI, .86–1.68]) did not differ statistically (Figure 2B).
Women assigned to ABC/3TC with ATV/r had a slightly
higher incidence of grade 3–4 gastrointestinal safety endpoint
compared to men on ATV/r (13% vs 7%) and to women receiv-
ing EFV (13% vs 6%) (Table 2).
Figure 2. Treatment and sex comparisons for virologic failure, safety, and tolerability endpoints. A, Subjects on abacavir and lamivudine (ABC/3TC), com-
paring atazanavir (ATV) vs efavirenz (EFV). B, Subjects on ABC/3TC, comparing women vs men. C, Subjects on tenofovir and emtricitabine (TDF/FTC), com-
paring ATV vs EFV. D, Subjects on TDF/FTC, comparing women vs men. Univariate analysis (u) stratified by screening human immunodeficiency virus type 1
(HIV-1) RNA, and based on all available data for the covariate. Multivariable (m) analyses were adjusted for race/ethnicity (white, black, Hispanic), intrave-
nous drug use, HIV-1 drug resistance genotype screening, age quartiles, CD4 cell count (4 categories), HIV-1 RNA level (4 categories), history of AIDS-
defining event, and hepatitis B or C. Multivariable analysis excluded participants of “other” race/ethnicity due to small numbers. P value: likelihood ratio
test, for main effect in “overall” results, and interaction tests otherwise. All models are stratified by screening HIV-1 RNA group (<100 000 or ≥100 000
copies/mL); univariate and multivariable adjusted estimates are based on interaction model; treatment effects by sex and sex associations by treatment
are derived from the same model. Abbreviations: ABC/3TC, abacabir; lamivudine; ATV/r, atazanavir/ritonavir; CI, confidence interval; EFV, efavirenz; HR,
hazard ratio; TDF/FTC, tenofovir/emtricitabine.
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With TDF/FTC
Overall, the time to a safety endpoint was not significantly dif-
ferent for subjects treated with ATV/r compared with those
treated with EFV (HR, 0.91 [95% CI, .72–1.15]), [9] with no ev-
idence of a difference by sex (Figure 2C); for women and men,
the IRs were 21.36 vs 18.27 and 15.31 vs 18.01, respectively.
Likewise, time to safety endpoint was not significantly different
between women and men (Figure 2D). Safety endpoints are
summarized by type in Table 2.
Grade 3–4 gastrointestinal events occurred with similar fre-
quency in women (4%) and men (6%) receiving ATV/r with
TDF/FTC (Table 2).
Tolerability
Primary tolerability endpoints (modification of ATV/r or EFV)
data for A5202 have been published elsewhere [8, 9]. In
summary, time to modification was significantly longer with
ATV/r than EFV when combined with ABC/3TC (Figure 2A);
there was no significant difference in time to modification with
ATV/r or EFV plus TDF/FTC (Figure 2C). The third drug
effect did not significantly differ by sex with either NRTI
(Figure 2B and 2D). Comparing women to men, with either set
of NRTIs, there was no apparent difference in time to discon-
tinuation of either third drug (Figure 2B and 2D).
The most common reason for modification of a third drug
was noncompliance with study medications or visits, which
was identified in 7% of women and 10% of men.
Pharmacokinetics Analyses for ATV
The population model included 2195 ATV concentration
values from 815 of 926 (88%) participants who initiated ATV.
Parameter estimates for ATV obtained from the structural pop-
ulation pharmacokinetic model were clearance equal to 7.9 L/
hour (95% CI, 7.6–8.2 L/hour), volume of distribution equal to
86 L (95% CI, 78–94 L), and absorption rate constant equal to
0.46 hour-1 (95% CI, .37–.56 hour-1). ATV concentration
trough (C24h) data were available from 358 of 926 subjects
(39%). ATV oral clearance and trough concentrations were dif-
ferent by sex, with women having a higher exposure to ATV
than men (Table 3). The average CL/F of ATV in men was 0.8
L/hour (95% CI, .3–1.3 L/hour) faster than in women. The geo-
metric mean ratio of the ATV C24h for men to women was 0.72
(95% CI, .58–.89); however, there were no significant interac-
tions between dual NRTIs and sex (P≥ .10; Table 3).
Self-reported Adherence and Virologic Failure by Sex
With ABC/3TC
Reported rates of short-term 100% adherence at follow-up
visits week 8 through 96 with EFV ranged from 87% to 93% in
women and 89%–92% in men. Reported rates of 100% adher-
ence in the ATV/r arm ranged from 80% to 92% in women and
87%–93% in men.
With TDF/FTC
Reported rates of 100% adherence at follow-up visits week 8
through 96 with EFV ranged from 85% to 97% in women and
92%–93% in men. Reported rates of 100% adherence with
ATV/r with TDF/FTC ranged from 87% to 93% in women and
91%–92% in men.
Association With Adherence
Repeated measures analyses adjusted for third drug assignment
and stratified by screening viral load showed no significant as-
sociation between sex and reported adherence (100% vs <100%)
over weeks 8, 24, 48, 72, and 96 with ABC/3TC (odds ratio
[OR] for women vs men, 1.15 [95% CI, .83–1.60]; P = .42) or
with TDF/FTC (OR, 1.19 [95% CI, .84–1.67]; P = .35), and no
significant evidence that adherence differed by the third drug
(P = .63 and .47 with ABC/3TC, P = .99 and .92 with TDF/
FTC).
Subjects who reported <100% adherence and subjects not on
ART at week 8 had increased risk of VF compared to those re-
porting 100% adherence: HR, 2.20 (95% CI, 1.35–3.56) and
4.85 (95% CI, 2.53–9.31), respectively, for ABC/3TC (P≤
.0002); HR, 2.67 (95% CI, 1.56–4.62) and 4.89 (95% CI, 2.08–
11.48), respectively, for TDF/FTC (P≤ .0004), with no evidence
that this adherence association differed by third drug (P = .26
Table 2. Most Common Types of Grade 3–4 Safety Endpoints by Sex (While Initially Receiving Efavirenz or Atazanavir/Ritonavir)
Category





















General body 35 (9%) 11 (15%) 54 (15%) 17 (18%) 45 (12%) 14 (18%) 56 (14%) 8 (11%) 190 (12%) 50 (16%)
Hematology 8 (2%) 6 (8%) 2 (1%) 5 (5%) 11 (3%) 4 (5%) 6 (2%) 0 (0%) 27 (2%) 15 (5%)
Gastrointestinal 21 (5%) 1 (1%) 17 (5%) 6 (6%) 22 (6%) 3 (4%) 28 (7%) 10 (13%) 88 (6%) 20 (6%)
Metabolic 23 (6%) 2 (3%) 45 (12%) 10 (11%) 20 (5%) 6 (8%) 41 (11%) 8 (11%) 129 (8%) 26 (8%)
Neuropsychologic 26 (7%) 2 (3%) 22 (6%) 6 (6%) 10 (3%) 0 (0%) 8 (2%) 6 (8%) 66 (4%) 14 (4%)
Abbreviations: ABC/3TC, abacavir/lamivudine; ATV/r, atazanavir/ritonavir; EFV, efavirenz; TDF/FTC, tenofovir plus emtricitabine.
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with ABC/3TC, P = .98 with TDF/FTC) or by sex (P = .32 with
ABC/3TC, P = .27 with TDF/FTC).
DISCUSSION
This is the first randomized clinical trial (RCT) to identify a
higher risk of VF in women assigned to an ATV/r-containing
regimen compared to a regimen with EFV. In addition, we
found that women in the ATV/r arms had higher VF risk and
slower ATV clearance than men assigned to ATV/r.
Several meta-analyses of clinical trials and cohort studies have
evaluated responses to ART comparing women and men. Some
studies have suggested that women have higher rates of VF due to
poorer adherence and complex socioeconomic factors, whereas
other studies report comparable responses [5–7].
Few RCTs have had adequate enrollment of women to
provide statistical power to allow comparisons of responses to
specific antiretroviral agents between and within sex groups.
ACTG A5202 enrolled 1857 participants, of whom 322 (17%)
were women, making this the largest US-based randomized
comparison of different antiretroviral regimens in HIV-1–
infected women. Furthermore, this is one of the largest clinical
trials comparing responses to specific modern antiretroviral
regimens between HIV-1–infected women and men.
The finding of higher VF rates among women on ATV/r
compared to EFV was unexpected. Previous clinical trials that
compared virological responses with EFV-based regimens to
PI-based regimens have had variable results by sex. For
example, ACTG 384 randomized 980 persons to zidovudine
plus 3TC, or stavudine plus didanosine, each combined with
EFV, nelfinavir (NFV), or EFV plus NFV. Eighteen percent
(n = 176) of participants were women. This study found no
evidence of significantly different virologic response rates by
sex [12, 13].
ACTG 5142 was an open-label randomized study that com-
pared 3 regimens for initial therapy: EFV plus 2 NRTIs; lopinavir/
ritonavir (LPV/r) plus 2 NRTIs; and LPV/r plus EFV [14]. The
study enrolled 757 subjects, of whom 20% (n = 151) were
women. In a multivariable Cox proportional hazards model
stratified by baseline factors, women had a greater risk of VF
than men (HR, 1.38 [95% CI, 1.01–1.89]) [14]. However, no
significant differences were found in time to VF when compar-
ing EFV to LPV/r in women [15].
We hypothesized that the higher VF rate in A5202 was
related to lower adherence or tolerability of ATV/r in women.
However, we found no evidence suggesting lower adherence in
women on ATV/r compared to women on EFV or compared
to men on ATV/r based upon a validated self-report question-
naire [16]. However, the adherence measure used has limita-
tions as it is based upon self-report and was limited to the week
preceding its completion.
We did not find a significant difference in safety or tolerabili-
ty endpoints comparing ATV/r to EFV between men and
women. There was trend evidence of higher frequency of grade
3–4 gastrointestinal events among women compared to men on
ATV/r with ABC/3TC (Table 2), yet this pattern was not seen
with TDF/FTC. Of note, not all grade 1 and 2 adverse events
were collected in this study, so we cannot assess their contribu-
tion to adherence or virologic outcomes. Previous studies have
demonstrated higher rates of gastrointestinal side effects in
women than in men on ritonavir-boosted PIs. For example, in
the Abbott study M98-863 (that compared LPV/r vs NFV, each
Table 3. Atazanavir Plasma Pharmacokinetics by Sex, and Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Treatment Arms
Group
Model-Based ATV CL/F Observed ATV Ctrough (22–25 h Postdose)
No. aMean ATV CL/F, L/h (± SD) P Value No. bMean ATV Ctrough, ng/mL (Range) P Value
Overall
Men 680 8.4 (2.4) .004c 299 562 (108–3782) .003c
Women 135 7.6 (2.8) 59 783 (638–960)
TDF/FTC
Men 338 8.6 (2.3) .3d 147 574 (108–3782) .1d
Women 68 8.0 (2.8) 26 670 (125–2500)
ABC/3TC
Men 342 8.2 (2.4) 152 550 (125–3391)
Women 67 7.2 (2.8) 33 886 (124–4985)




c Satterthwaite t test.
d Interaction (sex nucleoside reverse transcriptase inhibitor treatment arm) P value.
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with 2 NRTIs), women had similar response rates to men, but
rates of nausea and dyspepsia were higher in women [17].
Although the cause of higher VF rates among women on
ATV/r in our study is uncertain, our pharmacokinetic study find-
ings that women had slower ATV clearance and higher mean
before-dose ATV concentration suggests a hypothesis that higher
ATV levels may lead to higher rates of low-level (unmeasured)
toxicity that could affect outcomes. An exploratory analysis of
A5202 pharmacokinetics trended in the direction of a greater risk
of safety endpoint among subjects with slower ATV clearance,
but this association did not reach statistical significance [18].
It is notable that in A5202 a greater proportion of women re-
ported black race compared to men. It is possible that pharma-
cogenetic differences between racial groups could contribute to
drug metabolism differences attributed to differences by sex. If
this were the case, one would expect this difference to be demon-
strated most significantly among the EFV-treated participants, as
a higher prevalence of slow EFV clearance has been described
among blacks and Hispanics than whites [19]. However, we did
not see differences in virologic outcomes or safety endpoints
comparing women on EFV to men on EFV in our study. Phar-
macokinetic differences in ATV/r metabolism among racial
groups are less well described. In our pharmacokinetic substudy,
there was evidence that ATV/r clearance was associated with VF
and this association differed by sex and race; however, there was
no significant evidence that the differential association of ATV/r
clearance with VF by sex differed by race/ethnicity [18].
The results of this study offer new insight into potentially
important sex-based differences in treatment outcomes with
modern regimens for HIV treatment–naive patients. This is the
first RCT to identify a significantly greater risk of VF among
women treated with ATV/r vs EFV in combination with ABC/
3TC or TDF/FTC. These findings may have important clinical
implications given that ritonavir-boosted PIs are often favored
over EFV for women of childbearing potential. Moreover,
ATV/r is currently a preferred treatment for pregnant women,
and although EFV is listed under pregnancy risk category D,
the recent perinatal guidelines have been modified to allow
women who become pregnant while taking EFV to remain on
this agent as the greatest teratogenicity risk appears to be in the
early first trimester. EFV is also a now recommended as a treat-
ment option for pregnant women who initiate ART after the
first trimester [20]. The findings of the current study should
warrant additional investigation of antiretroviral regimens in
RCTs and cohorts with large enrollment of women.
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